Fourier Health

The models do the work and the humans check it, which is the arrangement that distinguishes an AI product from a services business with AI attached. Classification, labelling, structuring and summarisation of inbound records are all performed automatically, and the proprietary clinician network reviews and validates output rather than producing it. That is the opposite of the human scribe model this index grades down elsewhere, where a workforce drafts and software assists. One qualification kept in view rather than applied against the grade: the company describes using best in class large language models rather than models it owns, so the differentiation sits in the pipeline, the specialty configuration, the attribution layer and the clinician network rather than in the underlying model.

Among the better described oversight models in this category, combining two things most competitors have only one of. A proprietary network of specialist clinicians reviews and validates summaries, which is a human gate staffed by people with the training to catch a clinical error rather than a formatting one, and the company states this layer also feeds continued improvement of its models. Separately, attribution traces every summarised element back to its source location in the original records, so a reviewer can verify any assertion without leaving the product. Held at B because the parameters are undisclosed: it is not stated whether every summary is reviewed or a sample, at what rate, what reviewers find when they look, or what happens when a summary and its source disagree. No confidence signal, threshold or abstention behaviour is described. Ask for the review rate and the error rate it produces, since a clinician network that never reports finding anything is not an oversight layer.

One strong output level property and no model level disclosure. The strong part is attribution: every summarised element can be traced to where it appears in the original medical records, which the company frames explicitly as accountability and audit proofing rather than as a convenience feature, and that is the right framing for a category whose failure mode is silent. Against that, no model or model family is named beyond a reference to best in class large language models, no accuracy figure exists, no omission measure is published, and no evaluation methodology or model card was located. Ask which models the pipeline uses and whether patient content reaches a third party inference provider.

Commercial validation without a published measure of benefit, which this index grades C. An 8.4 million dollar seed round in October 2025 led by Yosemite with several named participating funds is real external diligence, the founding team carries verifiable operating history at Redox and InfiniteMD, and a listing on the AVIA marketplace means an outside party assessed the product for its catalogue. Deployment is described as dozens of provider organisations and not one is named. No case study, no quantified outcome, no accuracy data and no independent evaluation was located. For a company founded in late 2023 that is unsurprising, but it means nothing published establishes how well the summaries perform.

The clinician network is simultaneously the strongest oversight feature on this record and its largest privacy exposure, and both halves belong in the assessment. A proprietary network of specialist clinicians reads patient records in order to validate summaries, which means identifiable clinical content reaches people outside the treating organisation and outside the vendor's own employees. This index recorded the same duality for Speke, where a human review workforce delivered the best oversight in its lane and the widest PHI surface, and told buyers to evaluate the two as one decision. The same applies here. Additionally, no retention period, de identification posture or training use commitment was located, and the company states the review layer supports continued improvement of its models, which implies reviewed content informs training without bounding it. Establish where the clinician network is located, how it is contracted, what it can see, and what is retained.

No HIPAA compliance statement and no business associate agreement terms were located on any retrieved surface. Not Rated records absent evidence. The agreement chain matters more than usual here because of the clinician review network: establish whether those clinicians are employees, contractors or a separate entity, and how they are covered.

No SOC 2, HITRUST, ISO 27001 or other attestation was located, and no trust centre or security page was found. Not Rated reflects absent retrieval rather than an assessed weakness, and is unremarkable for a company at this stage, but it should be the first item requested given that records flow to an external review network.

No FDA clearance, device authorisation or clinical decision support exemption analysis was located. Not Rated reflects absent retrieval. The product summarises and triages rather than diagnosing or recommending treatment, so the scoping question is milder here than for several records in this category, but pre visit readiness assessment and document triage do shape what a clinician sees and in what order, which is worth raising.

The grade describes disclosure and incentive structure, and the credits are real. Attribution to source, a clinician verification layer and the company's own framing around veracity and auditability are the right instincts for this category, and more than most competitors at this stage offer. Against that, the commercial framing places the work inside the revenue cycle explicitly: the company describes the process as reimbursable, and describes the benefit as improving clinical decision making while increasing revenue through better risk capture and coding accuracy. Risk capture is the same gradient this index tracks across the category, and a summarisation layer whose value is partly expressed in coding accuracy is operating on the documentation that determines payment. Nothing here suggests inflation, and the counterweight of clinician verification is genuine, but the incentive should be visible to a buyer. Separately, no fairness, subgroup or demographic performance disclosure was located.

Unusually strong on standards and thin on named systems, which is the reverse of most records here and reflects the founding team's background building a major interoperability platform. Named protocols rather than vague claims: SMART on FHIR and HL7 version 2 for integration, bidirectional exchange through HL7 FHIR APIs, health information exchange connectivity for retrieving records the organisation does not hold, and user interface embedding inside systems such as Epic. Delivery is genuinely flexible, covering EHR embedding, inbox push, API and a standalone web application, with output as structured fields or as a PDF. The company also describes aligning with existing ambient documentation workflows rather than competing with them, which is a thoughtful position. Held at B because Epic is the only EHR named and no customer integration is evidenced, so breadth is asserted through protocol support rather than demonstrated.

No hosting model, cloud provider, region, residency commitment or customer hosted option was located. The several delivery routes described, EHR embedding, inbox, API and web application, describe how output reaches a user rather than where processing happens. Not Rated reflects absent retrieval. Residency deserves attention here because records also flow to an external clinician review network, so the question is not only where the software runs but where the reviewers are.

No price, tier or pricing mechanism was located. Not Rated is the house convention for absent pricing rather than a low grade. One commercial claim needs unpacking rather than crediting: the company describes its process as reimbursable because it sits within the revenue cycle. That is not a statement about what the product costs, and a buyer should establish precisely what it means, since a claim that a vendor's work is billable under existing codes is a materially different proposition from a claim that it improves revenue, and the two are easily conflated in a sales conversation.

Configurable rather than broad, which is the more useful property for summarisation. Summaries are shaped to specialty and use case, with oncology, geriatrics and rheumatology named as examples, and the same underlying records produce different outputs depending on what the summary is for. Named workflows span referral management, pre visit readiness assessment, document labelling and triage, and record intake automation, which covers the front door of a practice rather than only the clinical encounter. Graded B rather than A because the specialty configuration is described as a capability rather than demonstrated through instrument level behaviour in any named specialty, and because no care setting beyond ambulatory provider organisations is addressed.